Allergan Aesthetics to Acquire Soliton and its Resonic Device for ~$550M

 Allergan Aesthetics to Acquire Soliton and its Resonic Device for ~$550M

Shots:

  • Soliton to receive $22.60 /share in cash for its all outstanding share making the total deal value $550M
  • The acquisition adds Soliton’s Rapid Acoustic Pulse technology platform to Allergan Aesthetics’s portfolio for improvement in appearance of cellulite in the buttocks and thighs by using rapid high-frequency sound waves to disrupt targeted cellular structures and connective tissue
  • The technology complements Allergan Aesthetics’ portfolio of body contouring treatments includes CoolSculpting Elite. Resonic has received FDA clearance for tattoo removal in conjunction with laser and has demonstrated clinical results in fibrotic scars

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post